Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts At Tertiary Care Hospital in Karachi.

Jinnah Postgraduate Medical Centre

Status and phase: Invitation-only; Early Phase 1

Conditions: Cutaneous Warts

Treatments: Drug: Furosemide

Study type: Interventional

Funder types: Other

Identifiers

NCT06821594

NO.F.2-81/2024-GENL/22/JPMC

Details and patient eligibility

About

Identify the effects of combined intralesional furosemide 20mg/2ml and digoxin 0.5mg/2ml in cutaneous warts given weekly are rather safe and effective treatment for cutaneous warts, focusing on their effectiveness and safety, at a tertiary care hospital in Karachi, Pakistan.

Full description

Cutaneous warts are benign growth caused by human papilloma virus. Virus have more than 100 types of which few are responsible for cutaneous disease. Both injection furosemide and digoxin cause decrease intracellular potassium levels by interacting with cell membrane ion co-transporters (Na+/K+-ATPase and Na+-K+-2Cl-co-transporter-1) thereby causing delay in viral replication. The purpose of study is to evaluate the effects of both furosemide and digoxin given 0.2 ml once weekly for five weeks on viral warts.

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients presenting with greater than or equal to two warts
2. Either gender.
3. Age 18 - 60 years. -

Exclusion criteria

1. Pregnant or lactating women.
2. Patient not giving informed consent.
3. Patient received any treatment in the last 3 months period.
4. Patient with acute illness and immuno-suppressive disease.
5. Patient taking immuno-suppressive drugs.
6. Patient having hypersensitivity to any investigational medicine.
7. Patient having cutaneous warts on face and genitals.
8. Patient having cardiovascular disease.
9. Patient having renal disease. -

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

Patients

Experimental group

Description:

Patients with age between 18-60 years having more than two cutaneous warts will be given combined intralesional furosemide (20mg/2ml) and digoxin (0.5mg/2ml) 0.2 ml at the base of warts once weekly for five weeks

Treatment:

Drug: Furosemide